CTLA4 and hypothyroidism: It has been reported that the incidence of irAEs with CTLA-4 inhibitors is 0-17% for hypopituitarism, 4.3-11.0% for hypothyroidism, 2.0% for hyperthyroidism, and <2% for hypoadrenocorticism.